UBE3A-mediated regulation of imprinted genes and epigenome-wide marks in human neurons


To link to this article: http://dx.doi.org/10.1080/15592294.2017.1376151

Accepted author version posted online: 19 Sep 2017.

Submit your article to this journal

View related articles

View Crossmark data
Title: UBE3A-mediated regulation of imprinted genes and epigenome-wide marks in human neurons

Authors: S. Jesse Lopez¹⁻⁴, Keith Dunaway¹⁻⁴, M. Saharul Islam¹⁻³, Charles Mordaunt¹⁻³, Annie Vogel Ciernia¹⁻³, Makiko Meguro-Horike⁶, Shin-ichi Horike⁶, David J. Segal²⁻⁵ and Janine LaSalle¹⁻⁴

Affiliations: ¹Medical Immunology and Microbiology, ²Genome Center, ³MIND Institute, ⁴Integrative Genetics and Genomics, ⁵Biochemistry and Molecular Medicine, University of California, Davis, CA 95616; ⁶Advanced Science Research Center, Kanazawa University, 13-1 Takaramachi, Kanazawa 920-8640, Japan

Corresponding Author: Janine LaSalle, 3428 Tupper Hall, 1 Shields Avenue, Davis, CA 95616, (530) 754-7598, jmlasalle@ucdavis.edu or David Segal, 4512 GBSF, 451 Health Sciences Drive, Davis, CA 95616, (530) 754-9134, djsegal@ucdavis.edu

Abstract

The dysregulation of genes in neurodevelopmental disorders that lead to social and cognitive phenotypes is a complex, multilayered process involving both genetics and epigenetics. Parent-of-origin effects of deletion and duplication of the 15q11-q13 locus leading to Angelman, Prader-Willi, and Dup15q syndromes are due to imprinted genes, including UBE3A, which is maternally expressed exclusively in neurons. UBE3A encodes a ubiquitin E3 ligase protein with multiple downstream targets, including RING1B, which in turn monoubiquitinates histone variant H2A.Z. To understand the impact of neuronal UBE3A levels on epigenome-wide marks of DNA methylation, histone variant H2A.Z positioning, active H3K4me3 promoter marks, and gene
expression, we took a multi-layered genomics approach. We performed an siRNA knockdown of *UBE3A* in two human neuroblastoma cell lines, including parental SH-SY5Y and the SH(15M) model of Dup15q. Genes differentially methylated across cells with differing UBE3A levels were enriched for functions in gene regulation, DNA binding, and brain morphology. Importantly, we found that altering UBE3A levels had a profound epigenetic effect on the methylation levels of up to half of known imprinted genes.

Genes with differential H2A.Z peaks in SH(15M) compared to SH-SY5Y were enriched for ubiquitin and protease functions and associated with autism, hypoactivity, and energy expenditure. Together, these results support a genome-wide epigenetic consequence of altered UBE3A levels in neurons and suggest that UBE3A regulates an imprinted gene network involving DNA methylation patterning and H2A.Z deposition.

**Key words:**

autism, epigenetic, imprinting, DNA methylation, histone modification, chromatin
Introduction

Autism spectrum disorder (ASD) is a developmental disability characterized by social and communication impairments and repetitive behaviors with an estimated prevalence of 1 in 68\(^1\). Causes of ASD vary immensely among those affected involving a variety of genetic mutations as well as multiple environmental risk factors\(^2\text{--}^4\). Adding to the complexity of ASD etiology, genes with *de novo* variants are enriched for functions involving chromatin modification, developmental transcription factors, and signal transduction pathways\(^5\text{--}^7\). Epigenetic marks, such as DNA methylation and histone modifications, have also been observed to be critically important to proper brain development\(^8\text{,}^9\). Additionally, aberrant epigenetic regulation has been observed at the interface of genetic and environmental risk interactions implicated in ASD\(^10\text{--}^12\).

Genomic imprinting, whereby expression of a subset of mammalian genes are restrained to one parental allele, is a central epigenetic inheritance pattern relevant to ASD. Presently, imprinting is understood as a mechanism aimed at controlling the amount of maternal resources allocated to the offspring from conception to weaning\(^13\).

Imprinted genes are members of various gene families corresponding to diverse biochemical processes and are regulated by associated imprinting control regions (ICRs), which exhibit parent-of-origin epigenetic modifications that govern the imprinting of the locus\(^14\). Some imprinted genes have been observed to associate in an imprinted genes network (IGN) that controls embryonic growth and differentiation\(^15\). Similar to regulation of ICRs, IGN expression was observed to be mediated by an epigenetic effect through recruitment of chromatin-modifying partners\(^16\text{,}^17\). The realization that IGN
genes are coordinately regulated brings a new perspective that has not been previously examined in neurodevelopment or the etiology of ASD.

The human neurodevelopmental 15q11.2-q13.3 locus is a region of particular interest to the study of how epigenetics and imprinting disorders lead to ASD. Deletions of the 15q11.2-q12 locus on the paternal or maternal allele are responsible for the reciprocal disorders of Prader-Willi (PWS) or Angelman (AS) syndromes, respectively. In contrast, maternal duplications, lead to chromosome 15q11.2-q13.3 maternal duplication (Dup15q) syndrome, a genetic cause of ASD. *UBE3A*, which encodes an E3 ubiquitin ligase, is the imprinted gene most likely responsible for maternal-specific effects of 15q11.2-q13.3 deletion or duplication disorders \(^1^8\). *UBE3A* has known ubiquitin ligase function targeting multiple proteins for degradation \(^1^9,2^0\). However, it has also been shown to have transcriptional co-activator functions at steroid hormone receptors involving direct binding to the transcription complex \(^2^1,2^2\). *UBE3A* is localized in cytosolic and nuclear compartments and at both the pre- and post-synaptic locations and may play a diverse role in multiple cellular and transcriptional events in neurodevelopment \(^2^3\).

The role of deficient UBE3A levels in AS has been well established; however, the pathogenic role of increased UBE3A levels in Dup15q syndrome remains untested. We previously showed that both Dup15q brain and a neuronal cell culture model exhibit significant global DNA hypomethylation enriched over autism candidate genes impacting their transcriptional stability \(^2^4\). Dup15q is one of the most common CNVs observed in ASD and is characterized by increased expression of maternally expressed *UBE3A* \(^2^5-2^7\). While the specific role of *UBE3A* in the ASD phenotype of Dup15q
syndrome is not currently known, we observed a link between UBE3A overexpression and histone H2A.Z epigenetic modifications on genes with functions at neuronal synapses, transcriptional regulation, and signal transduction pathways. This suggests that UBE3A might influence neuronal maturation by directing chromatin patterning. Additionally, we proposed a mechanism by which UBE3A regulates H2A.Z monoubiquitination via degradation of RING1B, a known UBE3A target. This interaction may explain the role UBE3A plays in the observed hypomethylation of Dup15q.

In this study, we took a multi-layered genomics approach to understand how UBE3A affects the epigenome in Dup15q and Angelman syndromes. Integrating whole genome bisulfite sequencing (WGBS), transcriptome sequencing (RNA-seq), and chromatin immunoprecipitation sequencing (ChIP-seq), we developed an epigenomic profile of the dysregulation caused by aberrant levels of UBE3A in human neuronal cell culture models. We observed strong overlap between genes with differentially methylated regions (DMRs) and histone peaks of H3K4me3 and H2A.Z. These UBE3A-altered genes were enriched for imprinted genes with alterations to H2A.Z gene body localization.

Results

To understand the role of UBE3A in epigenetic regulation genome-wide, we first performed triplicate siRNA knockdowns of UBE3A (siUBE3A) or control (siCTL) in a human neuronal cell line (SH-SY5Y) and a chromosome duplication model of Dup15q syndrome [SH(15M)]. Compared to the parental SH-SY5Y cells treated with siCTL, UBE3A protein levels in similarly treated SH(15M) cells were 30% higher, while cells
treated with siUBE3A were 90% lower in SH-SY5Y and 70% lower in SH(15M) (Fig. 1A). Compared to the siCTL of each parental cell line, knockdown efficiency of UBE3A was 90% in SH-SY5Y and 72% in SH(15M) (Fig. S1A). From these cell cultures, we isolated DNA for WGBS, RNA for RNA-seq, and chromatin for ChIP-seq of one histone mark of active promoters (H3K4me3) and one histone variant (H2A.Z) of active promoters and poised genes (Fig. 1B). From each dataset, we identified whole-genome methylation levels, differentially expressed genes, and histone peaks, respectively.

Four comparison groups were created to explore the consequences of UBE3A gain or loss within a different genomic context (Fig. 1A). These included: 1) the chromosome 15M effect (chr15M)(CTL-15M vs. CTL-SH); 2) reduced UBE3A in the context of normal 2X copy number (KDSH)(KD-SH vs. CTL-SH); 3) reduced UBE3A in the context of the 3X copy number (KD15M)(KD-15M vs. CTL-15M); and 4) the 15M effect with reduced UBE3A (chr15M-minus)(KD-15M vs. CTL-SH). These comparisons were performed on each genomic data set resulting in gene lists showing differentially methylated regions (DMR genes) (Δ% methylation ≥ 0.1, q < 0.01), differential expression (RNA genes) (P < 0.05), and differential histone peak levels (K4me3 or H2A.Z genes) (q < 0.01) (Fig. 1C and S3-S4). Across all comparisons, genes with DMRs were the most numerous, while genes showing differential H2A.Z peaks were least prevalent. Increase of UBE3A from the chromosome 15M effect showed the fewest differentially expressed genes compared to the three knockdown comparisons. There were distinctions between cell lines as knockdown of UBE3A in SH-SY5Y had a profound effect on the levels of
H3K4me3 peaks in contrast to SH(15M), which had relatively few H3K4me3 peak differences following knockdown.

To examine the convergent effect of UBE3A expression differences, we determined the level of overlap between each dataset within each comparison group and calculated significance by Fisher’s exact test (Table 1). For all four comparisons, genes with DMRs significantly overlapped genes with differential H3K4me3 and H2A.Z peaks.

Differentially expressed genes did not significantly overlap with other datasets except in the KDSH comparison group, where it overlapped with differential H2A.Z genes. Genes with differential histone peaks H3K4me3 and H2A.Z overlapped in all comparisons except KD15M. All comparisons except KDSH showed similar patterns of overlap among all datasets, although KD15M comparison had relatively fewer differential H3K4me3 peaks (Fig. 2 and S2). The KDSH comparison showed the most unique pattern of overlapping epigenetic marks displaying a large overlap of DMR, H3K4me3, and H2A.Z associated genes, as well as a much greater number of differential H3K4me3 peaks.

To identify UBE3A-impacted pathways, functions, and traits, gene lists for each comparison group and dataset were analyzed by Gene Ontology (GO) analysis. DMR analysis showed a high enrichment for gene functions in DNA binding, RNA metabolism, and regulation of gene expression across all comparison groups (Fig. 3A). There was also strong enrichment of neurologically relevant terms including brain morphology and synaptic activity via the SNARE complex. Additionally, terms consistent with neurodevelopmental disorder physical characteristics, including broad face,
waddling gait, and *Genu recurvatum*, were enriched in the chr15M and KDSH groups. Enrichment of DNA binding, chromatin, and gene expression function were also seen for genes with differential H3K4me3 peaks within the chr15M and chr15M-minus groups (Fig. 3B). These two comparison groups derived from SH(15M) cells were also enriched for genes associated with impaired passive avoidance and fear-related response behavioral phenotypes. No significant enrichment was observed for the KD15M group. The KDSH group, which showed the largest effect on differential H3K4me3 peaks, also had the most unique GO term enrichment, with genes strongly enriched in epigenetic regulation including the PRC1 and polycomb complexes.

Differentially expressed genes showed a separation of GO term enrichments between gain and loss of *UBE3A* (Fig. 3C). The chr15M comparison was uniquely enriched for genes involved in glial and neuronal cell development. The three *UBE3A* knockdown comparison groups had a large term overlap including regulation of translation, excitatory synapse, Spt-Ada-Gcn5-acetyltransferase (SAGA-type) complex, and abnormal imprinting. Genes from the abnormal imprinting term included imprinted X-linked genes *XIST* and *TSIX* as well as imprinted autosomal genes *KCNQ10T1*, *IGF2*, *GNAS*, and *PEG3* (Supplemental Data and Figure S5-S8).

While not all group comparisons showed significant GO term enrichment for genes with differential H2A.Z peaks, the chr15M comparison group modeling Dup15q syndrome was enriched for genes associated with autism, ASD, hypoactivity, energy expenditure, and obesity (Fig. 3D). Additionally, this group showed enrichment for genes with functions in ubiquitin-specific protease activity, protein secretion, and protein import into
nucleus. Interestingly, while the KDSH group contained the fewest genes with
differential H2A.Z peaks, these showed highly significant enrichment for imprinted
genes (Fig. 3E). Imprinted genes in this group included *IGF2*, *GNAS*, *DLK1*, and *RTL1*
(Supplemental Data). This group also contained genes enriched for epigenetic
regulation and fetal growth. No significant term enrichment was observed for the
KD15M nor the chr15M-minus comparison groups.

Given that several of the comparison groups were enriched for GO terms related to
imprinting, we further evaluated the mode and extent to which *UBE3A* affects imprinted
genes. We utilized a list of experimentally confirmed imprinted genes
(http://www.geneimprint.com/site/genes-by-species) and determined the level of overlap
with our datasets within each comparison group. For all comparison groups, genes with
DMRs were significantly enriched for imprinted genes determined by Fisher’s exact test
(Table 2). Additionally, each comparison group contained DMRs within known,
ubiquitously imprinted ICRs\(^\text{29}\) (Supplemental Data). For the KDSH comparison group,
genes with differential H2A.Z peaks were also significantly enriched for imprinted genes
including *IGF2*, *GNAS*, *DLK1*, and *RTL1*. These four imprinted genes along with non-
imprinted *EEF2* were also the only five genes to be overlapped between all datasets in
the KDSH group (Supplemental data). Genes with differential H3K4me3 peaks in the
chr15M comparison group also showed significant enrichment for imprinted genes.
We previously demonstrated that SH(15M) cells and Dup15q brain showed lower levels
of the histone H2A ubiquitin ligase RING1B, and genes epigenetically altered in
SH(15M) cells were enriched for higher gene body levels of H2A.Z, a ubiquitinated
target of RING1B\textsuperscript{24}. To further understand the connection between UBE3A levels and H2A.Z positioning at other imprinted genes and genome-wide, we compared levels of H2A.Z in four quadrants of H2A.Z binding in promoters, gene bodies, or both (Fig. S9). As expected based on our prior analysis,\textsuperscript{24} genes observed to show differential H2A.Z peaks across all four comparison groups were significantly enriched for gene body H2A.Z levels compared to all genes (Fig. 4A). Both SH(15M) cell line conditions showed an approximate 5% increase in the number of genes with both high promoter and gene body H2A.Z levels compared to their respective SH-SY5Y counterparts, which was significant by Fisher’s exact test ($P < 0.01$). Upon UBE3A knockdown in both cell lines, there was a significant average 7% loss of genes (both total genes and differential H2A.Z subset) in the high promoter and gene body H2A.Z quadrant coinciding with an approximate 7% increase in genes with low promoter and gene body H2A.Z levels (Fig. 4A). In contrast, upon UBE3A knockdown in SH-SY5Y, levels of gene body H2A.Z in EEF2, RTL1, and IGF2 increased by approximately two-fold compared to the CTL-SH (Fig. 4B and Fig. S10). As expected based on prior predictions,\textsuperscript{30} correlating DNA methylation levels with either gene body H2A.Z (Fig. S10) or promoter H2A.Z (Fig. S11) levels showed a general trend of anti-correlation. For both H2A.Z locations, genes with differential H2A.Z between all comparison groups were significantly enriched for high gene body DNA methylation and high H2A.Z levels (quadrant 2) compared to all genes, but showed no significant changes between cell types or knockdown conditions. Overall, these data support a model in which UBE3A levels alter gene body H2A.Z positioning, and suggest that UBE3A-mediated changes to methylation patterns at
imprinted genes are due, in part, to H2A.Z repositioning particularly for the lowest UBE3A level (0.1x in KDSH).

Discussion

Our multi-layered genomics analysis of the effect of UBE3A expression levels in human neuronal cell culture models has improved the existing evidence for the effect UBE3A has on the epigenome and resulted in several novel findings. First, our experiments revealed that both UBE3A gain and loss showed significant effects on DNA methylation leading to DMRs in genes involved in transcriptional regulation and brain development. Second, we gained new insights into the overlap of distinct epigenetic marks in response to UBE3A level changes. Third, these studies revealed a significant effect of knocking down UBE3A levels on the methylation of up to half of known imprinted genes, suggesting for the first time a pivotal role for UBE3A in a neuronal imprinted gene network. Fourth, our multi-layered approach revealed some interesting new insights about the degree of overlap between epigenetic marks of gene activity and transcript levels themselves in a controlled system. Together, these data give strong support for a genome-wide, epigenomic function of UBE3A by directing DNA methylation and H2A.Z positioning and reveal a novel UBE3A-mediated imprinted gene network in neurons. Our gene enrichment analyses of UBE3A-mediated changes to transcripts and epigenetic marks revealed some interesting insights into the diseases caused by altered UBE3A levels. DMR analysis revealed genes involved in brain morphology and synaptic vesicle activity as well as genes implicated in ASD-relevant physiologic deficits including broad face, waddling gait, and Genu recurvatum. ChIP enrichment for H3K4me3 in the
duplicated chromosome comparison groups (chr15M and chr15M-minus) revealed genes involved in early embryonic and synaptic development and behavioral and impaired learning phenotypes typical to ASD. Differentially expressed genes resulting from duplication of *UBE3A* (chr15M) were enriched in neurogenesis processes while UBE3A knockdown (KDSH, KD15M, and chr15M-minus) revealed genes involved in synaptic activity, stress response, and abnormal imprinting. Most strikingly, although ChIP enrichment of H2A.Z revealed the fewest genes, these genes are strongly implicated in autism and a significant subset are other imprinted genes. Our data showing significant overlapping genes with UBE3A-mediated differential methylation and H2A.Z peaks contributes further understanding to the inter-relationship between these epigenetic features. We previously observed that Dup15q patient brain samples showed global DNA hypomethylation that was also reflected in the SH(15M) cell line when compared to the parental SH-SY5Y. Additionally, *UBE3A* knockdown in both SH-SY5Y and SH(15M) resulted in the restoration of synaptic transcripts and RING1B levels but global DNA methylation levels that remained below those of the controls. Here, we identified DMRs that were both hypo- and hyper-methylated in response to both the 15M effect and differing levels of UBE3A (Figure S5). The hypothesized link between UBE3A and DNA methylation changes is through RING1B, an E3 ligase in the human polycomb repressive 1 complex (PRC1). RING1B monoubiquitinates H2A and H2A.Z, and is targeted for canonical ubiquitination and subsequent degradation by *UBE3A*. siRNA studies have shown that *RING1B* regulates the overall level of ubiquitinated H2A.Z in human cells and that monoubiquitinated
H2A.Z is associated with facultative heterochromatin,\textsuperscript{31} suggesting that H2A.Z plays a role in epigenetic silencing by holding a poised chromatin state. Furthermore, exclusion of H2A.Z has been seen at sites of DNA methylation in the bodies of actively transcribed genes. Mutation of the \textit{MET1} DNA methyltransferase causing both losses and gains of DNA methylation genome-wide have resulted in reciprocal changes in H2A.Z deposition, while mutation of the \textit{SWR1} complex that incorporates H2A.Z resulted in genome-wide hypermethylation\textsuperscript{30}. Additionally, when DNA methylation is inhibited by azacytidine, H2A.Z-containing nucleosomes encroach into adjacent regions suggesting that histone variants associated with transcription or transcriptional poising may be limited to their functional targets by surrounding DNA methylation marks\textsuperscript{32}. Together, these results suggest a role of \textit{UBE3A} in chromatin changes associated with altered DNA methylation.

We found that \textit{UBE3A} knockdown resulted in loss of both promoter and gene body H2A.Z (Fig. 4A). H2A.Z has different functions depending on its deposition where presence within gene bodies is correlated with lower transcription levels and higher variability in expression patterns across tissue types and environmental conditions, and a major function of gene-body DNA methylation is to exclude H2A.Z from the bodies of highly and constitutively expressed genes\textsuperscript{33}. Conversely, the incorporation of monoubiquitinated H2A.Z into specific promoter-bound nucleosomes configures chromatin structure to poise genes for transcriptional activation\textsuperscript{34}. This suggests that H2A.Z positioning regulates a silencing and transcriptional activation via different mechanisms. While the widespread increase in H3K4me3 marks at promoters following
UBE3A knockdown has not been previously described, this effect may be a result of the previously described role for UBE3A in associating with and polyubiquitinating estrogen receptor\textsuperscript{35,36}. If UBE3A is required for degrading ER, the loss of UBE3A molecules likely results in widespread changes to promoters in which ER should only be transiently associated following ligand binding.

Through our overlapping datasets, we identified several imprinted genes affected by UBE3A transcriptionally and epigenetically, including DLK1, GNAS, IGF2, and RTL1. UBE3A is paternally imprinted in post-natal neurons and epigenetic influences on UBE3A levels in neurons are complex involving imprinting patterns inherited from oocytes and noncoding RNAs specific to neurons\textsuperscript{18}. A network of imprinted genes including IGF2 and DLK1 has been observed that controls embryonic growth and may be the basis for the implementation of a common mechanism of gene regulation during mammalian evolution\textsuperscript{15}. Additionally, disturbances in the regulation of imprinted genes have also been found to contribute to pediatric and adult cancer progression where deregulation of imprinted genes may be caused by aberrant DNA methylation at the ICRs controlling expression of individual or clustered imprinted genes\textsuperscript{37,38}. This provides evidence that IGNs are pivotal for proper development and that regulation on an IGN by UBE3A could be crucial for neurodevelopment specifically.

Our integrated epigenomic assays of UBE3A-mediated changes led to some somewhat surprising findings with regard to the lack of significant overlap between transcriptional changes and genes with altered epigenetics, including H3K4me3. However, other experiments are consistent with our findings. For instance, deletion of CFP1 from
mESCs causes loss of most H3K4me3 from expressed CpG island-associated genes yet there are minimal changes in transcript levels at these genes, assessed by microarray, or nascent transcription as measured by levels of RNA polymerase II by ChIP and genomic run-on sequencing. Similarly, deletion of SPP1 from yeast, resulting in gene-specific H3K4me3 reduction, has virtually no effect on steady-state or dynamically changing mRNAs or transcription. Strikingly, removal of H3K4 trimethylation, the mark that is most characteristic for transcription, has no effect on coding gene expression, in steady-state or dynamically changing conditions. In vitro, H3K4me3 is not required for transcription of a chromatinized substrate arguing against a globally instructive role for H3K4me3 in transcription. Instead, studies suggest the SET1 histone methyltransferase complex may rely on pre-existing transcription-dependent events to deposit H3K4me3 into chromatin, ruling out a strictly instructive role but explaining the strong correlation with transcription. The genes that were changed transcriptionally with UBE3A level changes in our system may have been out of synchrony with the more direct chromatin and DNA methylation changes that we observed. Additional studies that integrate multiple epigenetic marks with transcript changes are needed to fully understand the inter-relationships.

Here, we have shown the genome-wide, epigenomic effect on DNA methylation and histone modifications caused by aberrant levels of neuronal UBE3A. These epigenetic consequences were observed at genes involved in transcriptional regulation, brain development, as well as other imprinted genes. Our multi-layered approach also highlighted the disconnect between epigenetic modifications and transcriptional activity.
on a genome-wide scale and provides support that chromatin marks act as a fingerprint of directed genomic programming during development and not as an indicator of transient transcriptional changes. Finally, our study identified a novel role of UBE3A affecting transcription and epigenetics of other imprinted genes and provides evidence that UBE3A acts as a regulator in a novel, neuronal IGN. Genome-wide epigenetic changes related to UBE3A levels were primarily mediated through changes in H2A.Z deposition and DNA methylation with consequences on methylation of genes within a novel neuronal imprinted gene network.

Methods

Cell culture, siRNA knockdown, DNA, RNA and protein isolation

SH-SH5Y and SH-SY5Y-15M [SH(15M)] cells were grown as described\textsuperscript{28}. For siRNA knockdown, triplicate cultures of SH and SH15M cells were transfected in Accell SMARTpool transfection medium containing 1 μM of UBE3A or control siRNAs supplemented with 2.5% fetal bovine serum for 5 days. siRNA-mediated knockdown of UBE3A protein was carried out using the Accell SMARTpool (Dharmacon L-005137-00-0005) mixture of four siRNAs according to the manufacturer’s protocols. Accell non-targeting siRNA (Dharmacon D-001810-10-05) was used in knockdown controls. Briefly, approximately 400,000 SH or SH15M cells were plated in 12-well plates (DNA, RNA, and protein extraction) or approximately 5x10\textsuperscript{6} cell in 10 cm dishes (ChIP) and then incubated for 72 h in serum-free Accell SMARTpool transfection medium containing 1 μM of UBE3A siRNAs or non-target control. After 72 h, the medium was supplemented with serum-containing media. The cells were incubated for an additional 48 h for a total
of five days. UBE3A knockdown was confirmed by Western blot analysis. DNA was isolated using the Zymo Quick-gDNA MiniPrep Kit. RNA was isolated using the Qiagen RNeasy Mini Kit. Protein was isolated using Thermo Fisher RIPA Lysis and Extraction Buffer and centrifugation.

**Western blot**

Protein extracts (20–50 μg) were subjected to 4-20% precast polyacrylamide gel (Bio-rad). The samples were separated and transferred onto PVDF membranes for 130 min at a constant current of 100 mA. The membranes were blocked in TBS blocking buffer containing 5% non-fat dried milk for 1 h. Anti-E6AP (1:1,000, Bethyl laboratory, A300-352A) and anti-GAPDH (1:10,000, Advanced Immunochemical, Inc., 2-RGM2) were incubated with the membranes in blocking buffer containing 0.1% Tween and 5% non-fat dried milk overnight at 4°C. The membranes were then washed and incubated with horseradish peroxidase conjugated secondary antibodies, anti-mouse (Bio Rad, 170-5047) and anti-rabbit (Bio Rad, 170-6515) immunoglobulin (IgG) antibody in 1:10,000 dilution for 1 h. After membrane washing, bound antibody was detected using a Super Signal West Dura Extended Duration Substrate kit (Thermo Fisher Scientific Inc.). Protein bands were normalized according to GAPDH using the ImageJ densitometry analysis system.

**ChIP sample preparation**

Following siRNA knockdown, cells were cross-linked by adding formaldehyde to a final concentration of 1% and incubated at RT for 10 min. Cross-link reaction was stopped by adding glycine to a final concentration of 0.125 M and incubated at RT for 5 min. Cells
were rinsed twice with 1X PBS and, scraped, and pelleted. Pellets were resuspended in 200 uL 5 mM PIPES pH 8.0, 85 mM KCl with 10 uL IGEPAL and 10 uL PMSF protease inhibitor cocktail and incubated on ice for 10 min. Samples were briefly vortexed to release nuclei and centrifuged to pellet nuclei. Nuclei were then resuspended in 100 uL 50 mM Tris-HCl pH 8.1, 10 mM EDTA, 1% SDS with 10 uL PMSF and incubated on ice for 10 min. Chromatin was sheared on a Covaris E220 to an average length of 600 bp. Total chromatin (5%) was saved as input control and remaining chromatin was diluted 1:3 in 1 M Tris-HCl pH 8.1, 0.5 M EDTA, 5 M NaCl, 1.1% Triton X100, 0.01% SDS, and incubated with H3K4me3 antibody (Active Motif 39159) or H2A.Z antibody (Active Motif 39113) on a rotating platform at 4°C overnight. Magnetic protein G beads (15 µl; Cell Signaling Technology 9006) were added to each sample and incubated on a rotating platform for 2 h at 4°C. Magnetic beads were washed with RIPA buffer then settled in a magnetic rack followed by washes with 100 mM Tris-HCl pH 9.0, 500 mM LiCl, 1% IGEPAL, 1% deoxycholic acid then 100 mM Tris-HCl pH 9.0, 500 mM LiCl, 1% IGEPAL, 1% deoxycholic acid, 150 mM NaCl, respectively. Antibody/chromatin complexes were eluted with 100 uL 50 mM NaHCO3, 1% SDS. A total of 12 uL of 5 M NaCl was added and samples were incubated at 67°C overnight to reverse crosslinks. Samples were cooled and 1 uL RNaseA was added and incubated at 37°C for 30 min. DNA was purified using the Qiagen QIAquick PCR Purification Kit.

WGBS, RNA-seq, and ChIP-seq library preparation
WGBS libraries were prepared using the Illumina TruSeq DNA Methylation Kit (Illumina EGMK81312) according to manufacturer's protocol and three samples were pooled per lane on the HiSeq4000. RNA-seq libraries were prepared using the NEB NEBNext rRNA Depletion Kit (NEB E6310L) and NEBNext Ultra Directional RNA Library Prep Kit for Illumina (NEB E7420S) according to manufacturer's protocol and six samples were pooled per lane on the HiSeq4000. NGS libraries from ChIP DNA samples and input control DNA were prepared using the Kapa Biosystems KAPA Hyper Prep Kit (Kapa KK8504) according to manufacturer's protocol and 12 samples were pooled per lane on the HiSeq4000.

**Bioinformatics**

For all samples raw FASTQ files were filtered and trimmed using Trimmomatic\(^\text{47}\). For WGBS, reads were aligned to the human genome (hg38) using BS-Seeker\(^2\text{48}\). DMRs were called using the R packages DSS and bsseq and custom R commands\(^\text{49,50}\). For RNA-seq, reads were aligned to hg38 using TopHat\(^2\text{51}\). Differentially expressed genes were calculated using the edgeR Bioconductor package\(^\text{52,53}\). For ChIP-seq, reads were aligned using Bowtie\(^2\text{54}\). ChIP peaks and differential peaks were called using MACS\(^2\text{55}\). Gene Ontology was analyzed using GREAT\(^\text{56}\) for DMRs, H3Kme3, and H2A.Z gene lists, and Enrichr\(^\text{57,58}\) for DE genes lists.

**Differentially methylated region analysis**

All custom scripts and code are available for download at github.com/kwdunaway/WGBS_Tools as well as instructions on how to use them. Brief descriptions of each script are also on the wiki of this site.
Data Access

All sequencing data were deposited in the Gene Expression Omnibus (http://ncbi.nlm.nih.gov/geo), accession number pending. The authors declare no competing financial interests. Correspondence and requests for materials should be addressed to JML (jmlasalle@ucdavis.edu).

Author contributions

JML and DJS conceived the study. SJL, JML and DJS designed the study. SJL, KD, and MSI acquired the data. SJL, KD, CM, and AVC analyzed the data. SH15M cells provided by MH and SH. SJL, JML and DJS wrote the manuscript. All authors edited and approved the manuscript.

Acknowledgments

This work was supported by NIH R01ES021707, NIH P01ES011269, and EPA 83543201 (JML) and R01ES021707-S1 (SJL). This work used the Vincent J. Coates Genomics Sequencing Laboratory at UC Berkeley, supported by NIH S10 Instrumentation Grants S10RR029668 and S10RR027303 and the UC Davis MIND Institute Intellectual and Developmental Disabilities Research Center [U54 HD079125].
References


19. Huang, L. *et al.* Structure of an E6AP-UbcH7 complex: insights into ubiquitination


27. Scoles, H. A., Urraca, N., Chadwick, S. W., Reiter, L. T. & LaSalle, J. M.  
   Increased copy number for methylated maternal 15q duplications leads to 
   changes in gene and protein expression in human cortical samples. *Mol. Autism*  
   2, 19 (2011).


29. Court, F. *et al.* Genome-wide parent-of-origin DNA methylation analysis reveals 
   the intricacies of human imprinting and suggests a germline methylation- 

30. Zilberman, D., Coleman-Derr, D., Ballinger, T. & Henikoff, S. Histone H2A.Z and 
   DNA methylation are mutually antagonistic chromatin marks. *Nature* 456, 125– 
   129 (2008).

   Monoubiquitylation of H2A.Z Distinguishes Its Association with Euchromatin or  

32. Yang, X. *et al.* Gene reactivation by 5-aza-2’-deoxycytidine-induced 
   demethylation requires SRCAP-mediated H2A.Z insertion to establish 

33. Coleman-Derr, D. & Zilberman, D. Deposition of Histone Variant H2A.Z within 

34. Guillemette, B. *et al.* Variant Histone H2A.Z Is Globally Localized to the


41. Pavri, R. *et al.* Histone H2B Monoubiquitination Functions Cooperatively with


Table 1. Genomic datasets gene list overlaps

<table>
<thead>
<tr>
<th>Dataset 1</th>
<th>#Genes</th>
<th>Dataset 2</th>
<th>#Genes</th>
<th>Overlap</th>
<th>Expected</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>chr15M Dataset Gene Overlaps</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DMR</td>
<td>9778</td>
<td>RNA</td>
<td>962</td>
<td>412</td>
<td>443</td>
<td>0.98</td>
</tr>
<tr>
<td>DMR</td>
<td>9778</td>
<td>K4me3</td>
<td>1509</td>
<td>1188</td>
<td>696</td>
<td>3.2E-159</td>
</tr>
<tr>
<td>DMR</td>
<td>9778</td>
<td>H2A.Z</td>
<td>406</td>
<td>291</td>
<td>187</td>
<td>6.10E-26</td>
</tr>
<tr>
<td>RNA</td>
<td>962</td>
<td>K4me3</td>
<td>1509</td>
<td>69</td>
<td>68</td>
<td>0.49</td>
</tr>
<tr>
<td>RNA</td>
<td>962</td>
<td>H2A.Z</td>
<td>406</td>
<td>13</td>
<td>18</td>
<td>0.93</td>
</tr>
<tr>
<td>K4me3</td>
<td>1509</td>
<td>H2A.Z</td>
<td>406</td>
<td>146</td>
<td>29</td>
<td>5.80E-65</td>
</tr>
<tr>
<td><strong>KDSH Dataset Gene Overlaps</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DMR</td>
<td>7602</td>
<td>RNA</td>
<td>2557</td>
<td>762</td>
<td>917</td>
<td>1</td>
</tr>
<tr>
<td>DMR</td>
<td>7602</td>
<td>K4me3</td>
<td>14457</td>
<td>6926</td>
<td>5185</td>
<td>0.00E+00</td>
</tr>
<tr>
<td>DMR</td>
<td>7602</td>
<td>H2A.Z</td>
<td>24</td>
<td>15</td>
<td>8</td>
<td>7.10E-03</td>
</tr>
<tr>
<td>RNA</td>
<td>2557</td>
<td>K4me3</td>
<td>14457</td>
<td>1440</td>
<td>1744</td>
<td>1</td>
</tr>
<tr>
<td>RNA</td>
<td>2557</td>
<td>H2A.Z</td>
<td>24</td>
<td>7</td>
<td>3</td>
<td>0.02</td>
</tr>
<tr>
<td>K4me3</td>
<td>14457</td>
<td>H2A.Z</td>
<td>24</td>
<td>22</td>
<td>16</td>
<td>7.40E-03</td>
</tr>
<tr>
<td><strong>KD15M Dataset Gene Overlaps</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DMR</td>
<td>5126</td>
<td>RNA</td>
<td>2947</td>
<td>612</td>
<td>712</td>
<td>1</td>
</tr>
<tr>
<td>DMR</td>
<td>5126</td>
<td>K4me3</td>
<td>169</td>
<td>52</td>
<td>40</td>
<td>0.03</td>
</tr>
<tr>
<td>DMR</td>
<td>5126</td>
<td>H2A.Z</td>
<td>108</td>
<td>47</td>
<td>26</td>
<td>7.80E-06</td>
</tr>
<tr>
<td>RNA</td>
<td>2947</td>
<td>K4me3</td>
<td>169</td>
<td>25</td>
<td>23</td>
<td>0.4</td>
</tr>
</tbody>
</table>
### chr15M-minus Dataset Gene Overlaps

<p>| | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>RNA</td>
<td>2947</td>
<td>H2A.Z</td>
<td>108</td>
<td>11</td>
<td>15</td>
</tr>
<tr>
<td>K4me3</td>
<td>169</td>
<td>H2A.Z</td>
<td>108</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.9</td>
</tr>
<tr>
<td>RNA</td>
<td>2807</td>
<td>K4me3</td>
<td>2645</td>
<td>1025</td>
<td>1207</td>
</tr>
<tr>
<td>DMR</td>
<td>9115</td>
<td>RNA</td>
<td>2807</td>
<td>1025</td>
<td>1207</td>
</tr>
<tr>
<td>DMR</td>
<td>9115</td>
<td>K4me3</td>
<td>2645</td>
<td>1965</td>
<td>1137</td>
</tr>
<tr>
<td>DMR</td>
<td>9115</td>
<td>H2A.Z</td>
<td>128</td>
<td>84</td>
<td>55</td>
</tr>
<tr>
<td>RNA</td>
<td>2807</td>
<td>K4me3</td>
<td>2645</td>
<td>326</td>
<td>350</td>
</tr>
<tr>
<td>RNA</td>
<td>2807</td>
<td>H2A.Z</td>
<td>128</td>
<td>14</td>
<td>17</td>
</tr>
<tr>
<td>K4me3</td>
<td>2645</td>
<td>H2A.Z</td>
<td>128</td>
<td>79</td>
<td>16</td>
</tr>
</tbody>
</table>
Table 2. Genomic datasets imprinted gene overlaps

<table>
<thead>
<tr>
<th>Dataset</th>
<th>#Genes</th>
<th>Imprinted</th>
<th>Overlap</th>
<th>Expected</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>chr15M Imprinted Gene Overlap</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DMR</td>
<td>9778</td>
<td>234</td>
<td>122</td>
<td>108</td>
<td>0.037</td>
</tr>
<tr>
<td>RNA</td>
<td>962</td>
<td>234</td>
<td>3</td>
<td>10</td>
<td>1</td>
</tr>
<tr>
<td>K4me3</td>
<td>1509</td>
<td>234</td>
<td>24</td>
<td>16</td>
<td>0.046</td>
</tr>
<tr>
<td>H2A.Z</td>
<td>406</td>
<td>234</td>
<td>5</td>
<td>4</td>
<td>0.47</td>
</tr>
<tr>
<td><strong>KDSH Imprinted Gene Overlap</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DMR</td>
<td>7602</td>
<td>234</td>
<td>102</td>
<td>84</td>
<td>8.60E-03</td>
</tr>
<tr>
<td>RNA</td>
<td>2557</td>
<td>234</td>
<td>20</td>
<td>28</td>
<td>0.97</td>
</tr>
<tr>
<td>K4me3</td>
<td>14457</td>
<td>234</td>
<td>141</td>
<td>159</td>
<td>1</td>
</tr>
<tr>
<td>H2A.Z</td>
<td>24</td>
<td>234</td>
<td>4</td>
<td>0</td>
<td>1.30E-04</td>
</tr>
<tr>
<td><strong>KD15M Imprinted Gene Overlap</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DMR</td>
<td>5126</td>
<td>234</td>
<td>73</td>
<td>56</td>
<td>8.50E-03</td>
</tr>
<tr>
<td>RNA</td>
<td>2947</td>
<td>234</td>
<td>31</td>
<td>32</td>
<td>0.61</td>
</tr>
<tr>
<td>K4me3</td>
<td>169</td>
<td>234</td>
<td>2</td>
<td>2</td>
<td>0.56</td>
</tr>
<tr>
<td>H2A.Z</td>
<td>108</td>
<td>234</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>
### chr15M-minus Imprinted Gene Overlap

<table>
<thead>
<tr>
<th></th>
<th>DMR</th>
<th>RNA</th>
<th>K4me3</th>
<th>H2A.Z</th>
</tr>
</thead>
<tbody>
<tr>
<td>Count</td>
<td>9115</td>
<td>234</td>
<td>2645</td>
<td>128</td>
</tr>
<tr>
<td>Size</td>
<td>114</td>
<td>19</td>
<td>37</td>
<td>1</td>
</tr>
<tr>
<td>Mean</td>
<td>100</td>
<td>31</td>
<td>29</td>
<td>1</td>
</tr>
<tr>
<td>P</td>
<td>4.40E-02</td>
<td>0.99</td>
<td>0.077</td>
<td>0.76</td>
</tr>
</tbody>
</table>
Figure legends

Figure 1. Multi-layered genomics analysis of SH-SY5Y and SH(15M) UBE3A siRNA knockdown reveals how altered UBE3A levels impact epigenomic patterns. A. UBE3A protein levels quantified from Western blot in SH(15M) and SH-SY5Y for siRNA control and UBE3A knockdown relative to GAPDH (blot in Fig. S1). Labeled are the four comparison groups used for differential genomic analyses. Error bars represent the mean ± SEM of three replicates. Significance by 2-way ANOVA P < 0.0001. B. Study design: following UBE3A siRNA knockdown and control treatment, each triplicate culture was harvested for DNA, RNA, or chromatin to assay DNA methylation, differentially expressed genes, or histone peaks, respectively. C. Table outlining results of the genomic assays for each comparison group by UBE3A levels. Each of the four comparisons generated independent lists of genes that overlapped with differential marks from each of the genomic assays.
Figure 2. Overlap of dataset gene lists shows effect of altered UBE3A levels on the epigenome. Size-dependent Venn diagrams show a graphical representation of the gene lists generated by each genomic assay for each comparison group. Circles indicate the relative number of genes for each dataset and show the level of overlap between datasets within each comparison group.
Figure 3. Gene Ontology enrichment reveals that UBE3A effects epigenetic regulation of neuronal development and imprinted genes. 

A. GO enrichment heatmap for DMR-associated gene lists for each comparison group. Significance of term enrichment by FDR q-value for each group is indicated by colored key. 

B. GO enrichment heatmap for differential H3K4me3-associated gene lists for chr15M, KDSH, and chr15M-minus comparison groups. Significance of term enrichment by FDR q-value for each group is indicated by colored key. 

C. GO enrichment heatmap for differentially expressed genes for each comparison group. Significance of term enrichment by Bonferroni P value for each group is indicated by colored key. 

D. GO enrichment for differential H2A.Z-associated genes in the chr15M comparison group. Significance of term enrichment by FDR q-value is represented by -log10 bar values. 

E. GO enrichment for differential H2A.Z-associated genes in the KDSH comparison group. Significance of term enrichment by FDR q-value is represented by -log10 bar values.
Figure 4. *UBE3A* knockdown in SH-SY5Y and SH(15M) changes H2A.Z promoter and gene body levels. **A.** Percent of genes with high or low promoter H2A.Z and high or low gene body H2A.Z from quadrants in Figure S5. Percent of total genes and percent of genes with differential H2A.Z peaks are shown for each cell type and siRNA condition. Comparisons indicate significance of the change in number of genes following *UBE3A* knockdown by Fisher’s exact test. (* P < 0.01, ** P < 0.001, **** P E 0)

**B.** Representative UCSC Genome Browser snapshot of *IGF2* showing tracks of each genomic dataset and highlighting increase of H2A.Z at imprinted genes.